NEWS & PRESS RELEASES:
January 10, 2024: PharmaNest attends the 2024 JP Morgan Healthcare Conference satellite events to develop strategic relationships in the Drug Development and Investors communities.
January 6, 2024: Alongside with PathAi and Histoindex, Dr. Mathieu Petitjean presents "FibroNest: single-fiber, Single-cell high content an high resolution digital pathology for the assessment of Liver Biopsies in NASH studies" at the 2024 NASH-TAG conference in Deer Park, UT, USA
November 8, 2023: Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials. (Press Release Here)
November 1, 2023: Dr. Mathieu Petitjean presents PharmaNest and its FibroNest digtal Pathology biomarkers and the 2023 BioNJ’s AI / Digital Health Day
October 13 2023: PharmaNest submits its Digital Pathology biomarker to the Drug Development Program / Biomarker Qualification program at FDA/ CDER (LOI here)
September 20, 2023: Dr. Mathieu Petitjean presents "FibroNest: single-fiber, Single-cell high content an high resolution digital pathology for the assessment of Liver Biopsies in NASH studies" at the Liver Meeting Forum / Paris NASH meeting in Paris, France
September 2, 2023: Dr. Mathieu Petitjean presents "High Resolution and single-fiber Digital Pathology and AI, from Liver Organoids to HCC and outcomes" at the 2023 ESBRA Conference in Graz, Austria
June 22, 2023: PharmaNest Launches Its Digital Pathology Spatially Resolved, Quantitative Tissue Panels to Quantify Tissue Injury and Inflammation in the Context of Fibrotic Conditions (Press Release Here)
June 19, 2023: PharmaNest to present six digital Pathology and AI abstracts at the International Liver Congress -EASL 2023, including liver related clinical outcomes prediction results in NASH (Press Release Here)
March 19, 2023: PharmaNest presents five abstracts to the Keystone Symposium on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies (list here).
January 4, 2o23, From the Icahn School of Medicine at Mount Sinai: Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease (Press Release here, published on line in Science Translational Medicine, weblink here)
November 3, 2022: PharmaNest Presents NASH Digital Pathology and AI Results With a Performance That Compares to Histological Stages and Imaging (Press Release here)
September 7, 2022: The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH (Press Release here)
June 20, 2022: PharmaNest to Present Eight Digital Pathology and AI Abstracts at the International Liver Congress 2022 (see press release here)
April 28, 2021, From GALMED Pharmaceuticals Ltd, Using FibroNest: Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment (see press release here)
November 12, 2021: PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021 (see press release here)
August 25,2021, From LIPOCINE Inc, Using FibroNest: Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study (see press release)
April 1, 2021: “New in vitro assay developed to test potential NASH drugs: An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery”, by Victoria Rees in Drug Target Review ( Article here)
March 29, 2021: Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting (see press release here) (see presentation here)
November 11, 2020: PharmaNest Announces New Pre-Clinical NASH and Clinical Liver Cancer Data to Be Presented at the AASLD | the Liver Meeting Digital Experience (TLMdX) 2020 (see press release here)
August 24, 2020: PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the EASL | Digital International Liver Congress 2020 (see press release here)
February 6, 2020: PharmaNest Announces Kidney and Lung fibrosis quantification Data to be Presented at the 2020 Fibrosis and Tissue Repair Keystone Symposium (see press release here)
October 30, 2019: PharmaNest Announces New Adult and Pediatric NASH Data to be Presented at the AASLD – Liver Meeting® 2019 (see press release here)
Sept 24, 2019: PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH (see press release here)
Offices:
100 Overlook Center, FL2, Princeton, NJ 08540
FibroNest Operations:
We deliver FibroNest worldwide via the Cloud.